Methods	Design: Cost‐effectiveness analysis conducted alongside an RCT, societal perspective. Costs were reported in 1995 US$
Participants	Population: Persons with schizophrenia, schizoaffective disorder, or bipolar disorder and a concurrent substance use disorder
Interventions	Intervention:
	Specialized treatment for dual disorders in an ACT team
	Comparator:
	SCM program with targeted substance abuse services
Outcomes	Cost/Cost‐effectiveness:
	ACT more effective and less costly than SCM in both substance abuse and quality of life comparisons.
	The relationship between the treatment received and benefit to cost ratio was curvilinear. During earlier periods SCM produced better outcomes per $10,000 invested than did ACT. During the final year of the study, ACT produced substantially better outcomes per $10,000 than SCM.
Notes